Cover Image
市場調查報告書

何杰金氏淋巴瘤的治療方法的全球市場:成長率、趨勢、預測

Global Hodgkin Lymphoma Treatment Market - Growth, Trends and Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 546541
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
何杰金氏淋巴瘤的治療方法的全球市場:成長率、趨勢、預測 Global Hodgkin Lymphoma Treatment Market - Growth, Trends and Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 211 Pages
簡介

本報告提供何杰金氏淋巴瘤的各種治療方法、治療藥的市場相關分析,疾病概要和現在/未來可利用的治療選擇,主要的促進、阻礙因素,市場規模趨勢預測 (今後6年份),各領域、各地區的詳細趨勢,近幾年的市場競爭的動向,主要企業簡介等調查。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 主要考察事項

第5章 市場概要、產業趨勢

  • 目前市場方案
  • 市場概要
  • 波特的五力分析

第6章 推動、市場的阻礙要素/機會/課題分析 (DROC分析)

  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 主要課題

第7章 全球輸卵管癌症市場:各領域

  • 治療方法的種類
    • 手術
    • 化療
    • 放射治療

第8章 全球輸卵管癌症市場:各地區的市場規模、佔有率預測

  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (德國,英國,法國,義大利,西班牙、葡萄牙,北歐各國,荷比盧三國等)
  • 亞太地區 (中國,日本,印度,澳洲、紐西蘭,韓國等)
  • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
  • 南美 (巴西,阿根廷等)

第9章 競爭環境

  • 企業合併、收購 (M&A) 分析
  • 新產品的銷售
  • 協定,產業合作、聯盟

第10章 企業簡介

  • Amgen Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly and Company
  • Roche
  • 其他

第11章 投資機會相關分析師的見解

第12章 市場未來展望

目錄

The global fallopian tube cancer market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by 2021.

As per a report by the American Cancer Society, an estimated 22,280 women in the United States are expected be diagnosed with ovarian cancer in 2016, and most of these are high-grade serous ovarian cancers (HGSC), which begin in a fallopian tube. The five-year survival rate for women, with all types of ovarian and fallopian cancer, is 46%. This type of cancer is diagnosed before spreading outside of the tubes in only about 15% of the cases. The survival rate for such cases is almost 90%.

Global Fallopian Tube Cancer - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

Rise in awareness about the type of cancer and available therapies

Increasing health care expenditure

Restraints

High cost associated with the surgery and therapy

Adverse side-effects of treatment and toxicity of drugs

Market Segmentation

The global fallopian tube cancer market has been segmented by type of therapy into surgery (salpingo-oophorectomy and cytoreductive/debulking surgery, among others), chemotherapy and radiation therapy. The drugs that can be used as chemotherapy agents include Taxol (Paclitaxel), Avastin (Bevacizumab), Cisplatin, Evacet (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride, Gemzar (Gemcitabine Hydrochloride), among multiple others. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

Amgen Inc.

AstraZeneca

Bayer

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

Celgene

Eli Lilly and Company

Roche

Others

What the Report Offers

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Deliveratives
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions
  • 1.7 Report Description

2. RESEARCH METHODOLOGY

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Study timeline
  • 2.4 Study Phases
    • 2.4.1 Secondary Research
    • 2.4.2 Discussion Guide
    • 2.4.3 Market Engineering & Econometric Model
    • 2.4.4 Expert Validation

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW AND INDUSTRY TRENDS

  • 5.1 Current Market Scenario
  • 5.2 Market Overview
  • 5.3 Porters Five Force Analysis
    • 5.3.1 Bargaining Power Of Suppliers
    • 5.3.2 Bargaining Power Of Buyers
    • 5.3.3 Degree Of Competition
    • 5.3.4 Threat Of Substitution
    • 5.3.5 Threat Of New Entrants

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Rise in Awareness About the Type of Cancer and Available Therapies
    • 6.1.2 Increasing Health Care Expenditure
  • 6.2 Market Restraints
    • 6.2.1 High-Cost Associated with the Surgery and Therapy
    • 6.2.2 Adverse Side Effects of Treatment and Toxicity of Drugs
  • 6.3 Market Opportunities
  • 6.4 Key Challenges

7. Global Fallopian Tube Cancer Market - Segmentation

  • 7.1 By Type of Therapy
    • 7.1.1 Surgery
      • 7.1.1.1 Salpingo-oophorectomy
      • 7.1.1.2 Cytoreductive/Debulking Surgery
      • 7.1.1.3 Others
    • 7.1.2 Chemotherapy
      • 7.1.2.1 Taxol (Paclitaxel)
      • 7.1.2.2 Avastin (Bevacizumab)
      • 7.1.2.3 Cisplatin
      • 7.1.2.4 Evacet (Doxorubicin Hydrochloride Liposome)
      • 7.1.2.5 Doxorubicin Hydrochloride
      • 7.1.2.6 Gemzar (Gemcitabine Hydrochloride)
      • 7.1.2.7 Others
    • 7.1.3 Radiation Therapy

8. Global Fallopian Tube Cancer Market - Regional Shares and Forecast

  • 8.1 North America
    • 8.1.1 United States
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 UK
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain & Portugal
    • 8.2.6 Scandinavia
    • 8.2.7 Benelux
    • 8.2.8 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 Australia & New Zealand
    • 8.3.5 South Korea
    • 8.3.6 Rest of Asia-Pacific
  • 8.4 The Middle East and Africa
    • 8.4.1 GCC
    • 8.4.2 South Africa
    • 8.4.3 Rest of the Middle East and Africa
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America

9. Competitive Landscape

  • 9.1 Merger and Acquisition Analysis
  • 9.2 New Product Launches
  • 9.3 Agreements, Collaborations & Partnerships

10. Company Profiles

  • 10.1 Amgen Inc.
  • 10.2 AstraZeneca
  • 10.3 Bayer
  • 10.4 Boehringer Ingelheim GmbH
  • 10.5 Bristol-Myers Squibb
  • 10.6 Celgene
  • 10.7 Eli Lilly and Company
  • 10.8 Roche
  • 10.9 Others

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

Back to Top